- Search Results
 
 
Ebola Vaccines Phase 2 Study Targets 1,500 Volunteers
Date Uploaded: Mar 28, 2015

Montserrado County Flag

 

 

Ebola Vaccines Phase 2 Study Targets 1,500 Volunteers

By Joseph Toe, LINA

MONROVIA, March 27 (LINA) - A total of 1,500 persons will be enrolled in Phase 2 of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) study, according to the Liberian-US joint clinical research team.

The team noted that the number, which more than doubles the 600 participants that were enrolled in Phase 1, will also increase the percentage of women in the study.

The above is part of several initiatives being developed by the team in addition to exploring the possibility of sharing the Phase 3 of the PREFVAIL study with other countries within the West African sub-region.

Addressing the daily Ebola press briefing of the Ministry of Information at the ministry Thursday, co-principal investigator on the team, Dr. Stephen Kennedy, said at least two additional blood samples would be obtained from all participants for at least one year to examine the durability of the immune responses.

Kennedy pointed out that participants should continue be enrolled in the Phase 2 PREVAIL study at Redemption Hospital through late April and follow up with them for at least six to 12 months post-vaccination to determine the durability of the immune responses.

According to him, these proposed changes are being reviewed by the US Food and Drug Administration and Liberia and US Institutional Review Boards.

Kennedy pointed out that Phase 3 component of the study had planned to enroll about 27,000 Liberians at risk of the Ebola virus infection.

He noted, however, that as a result of Liberia’s successful infection control and prevention strategy targeting Ebola, there has been only one new case since February 19, prompting the team to decide it is scientifically appropriate to develop additional vaccine sites in other West African countries to consider co-sharing the Phase 3 study.

“Discussions are currently underway to explore that possibility,” he said.

It will be recalled the vaccines, ChAd3-EBO-Z, developed by GlaxoSmithKline or VSV-ZEBOV, from NewLink Genetics/Merck versus a saltwater placebo injection were introduced in the country early this year.

LINA

latest headlines
‘Poverty Rate Still High In Africa,’ Says WB Lead Economist
World Bank Lead Economist and the author of the Africa’s Pulse Report, Punam Chuhan-Pole, has observed that with poverty rates still high in th ...more
African Media Group Condemns Killing Of Nigerian Journalist
The Media Foundation for West Africa (MFWA) says it has received with shock reports that Famous Giobaro, a desk editor with the state-owned Glory ...more
LNP Assures Female Contestants Of Full Protection
Police Inspector General Gregory Coleman has assured women vying in the October elections of full police protection during their campaign process ...more
WFP Official Urges Joint Efforts For ‘Zero Hunger’ Goal In Liberia
The World Food Program (WFP) Regional Director for West and Central Africa, Abdou Dieng, has called for collaborative efforts by Liberians to ach ...more
Apostle Suleman Coming To Liberia Again
The President and Founder of the Nigeria-based Omega Fire Ministries (OFM) international is due in the country for a two-day crusade beginning Ma ...more
Police Chief Nudges Youth To Embrace Peace
Police Inspector-General Gregory Coleman has called on Liberian youths to do away with violence and embrace positive thoughts and actions for the ...more
 
All rights reserved © 2013 - 2014
Liberia News Agency